TRIALSITEIQ PUBLIC FEASIBILITY SCORECARD · GRADE B-

NCT07563738: A 2-part Phase 1/2 Open-label Trial on ODM-212

Sponsor: Orion Corporation, Orion Pharma · Phase: PHASE1/PHASE2 · Area: ONCOLOGY · Target Enrollment: 229 pts

Competing Trials Overlap

14 Active Trials

Excess Burn Exposure

$471,240

Rescue Site Savings

+$314,160

Unlock Full NCT07563738 Backup Super-Site Packet ($49 One-Time Pass)

Download the complete list of top-decile low-cannibalization clinical sites, verified Principal Investigator (PI) direct emails/phones, and protocol optimization benchmarks.

Download $49 NCT07563738 Rescue Dossier →